

Blue Cross® and Blue Shield® of North Carolina (Blue Cross NC) | Healthy Blue + MedicareSM
(HMO-POS D-SNP)

Clinical Criteria Updates Effective May 4, 2025

Summary: The Pharmacy and Therapeutic (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for *Blue Cross NC*. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number

Please share this notice with other members of your practice and office staff.

Please note:

- The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by *Blue Cross NC* only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
May 4, 2025	CC-0267	Ebglyss (lebrikizumab-lbkz)	New
May 4, 2025	CC-0268	Lymphir (denileukin diftiox-cxdl)	New
May 4, 2025	CC-0269	Nemludio (nemolizumab-ilto)	New
May 4, 2025	CC-0270	Niktimvo (axatimab-csfr)	New
May 4, 2025	CC-0271	Tecelra (afamitresgene autoleucel)	New
May 4, 2025	CC-0012	Brineura (cerliponase alfa)	Revised
May 4, 2025	CC-0250	Veopoz (pozelimab-bbfg)	Revised
May 4, 2025	CC-0072	Vascular Endothelial Growth Factor (VEGF) Inhibitors	Revised

<https://bluecrossnc.com/providers/networks-programs/blue-medicare/healthy-blue-medicare>

Blue Cross and Blue Shield of North Carolina Senior Health, DBA Blue Cross and Blue Shield of North Carolina, is an HMO-POS D-SNP plan with a Medicare contract and a NC State Medicaid Agency Contract (SMAC). Enrollment in Blue Cross and Blue Shield of North Carolina Senior Health depends upon contract renewal.

®, SM are marks of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross Blue Shield Association.

NCBCBS-CR-071479-24-CPN71236 January 2025

Blue Cross and Blue Shield of North Carolina
Healthy Blue + Medicare
Clinical Criteria updates effective May 4, 2025

Effective Date	<i>Clinical Criteria Number</i>	<i>Clinical Criteria Title</i>	New or Revised
May 4, 2025	CC-0029	Dupixent (dupilumab)	Revised
May 4, 2025	CC-0201	Rybrevant (amivantamab-ymjw)	Revised
May 4, 2025	CC-0130	Imfinzi (durvalumab)	Revised
May 4, 2025	CC-0002	Colony Stimulating Factor Agents	Revised
May 4, 2025	CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
May 4, 2025	CC-0011	Ocrevus (ocrelizumab)/Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq)	Revised